Aushon BioSystems Inc. partnered up with Peking University Cancer Hospital to develop colorectal cancer-detection technology, aiming to predict when colorectal cancer migrates to the liver.
Aushon plans to use its suite of protein bio-marker detection technologies to develop predictive diagnostic markers for liver metastases of colorectal cancer, working with Dr. Jin Gu of Peking University Cancer Hospital. Gu focuses on studying how colorectal cancer metastasizes, seeking to identify bio-markers that might predict which patients may develop liver cancer, according to Aushon.
“We are very optimistic that this partnership will lead to the discovery and development of predictive diagnostic markers for primary colorectal cancer metastases in liver, and establishment of new treatment strategies to improve outcomes for our patients,” Gu said in prepared remarks.
The deal also gives Aushon the first crack at exclusive rights to some of the intellectual property created via the collaboration.
Billerica, Mass.-based Aushon bought out Thermo Fisher Scientific Inc.’s (NYSE:TMO) SearchLight protein array business in March 2009. The company tapped four diagnostics and pharmaceutical industry vets in January for its new scientific advisory board to help it identify new markets for its multiplex immunoassay platform.
The company’s collaboration with Peking University was initiated and facilitated by the U.S.-Chinese Anti-Cancer Assn. (USCACA).